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Perinatal Pandemic 
(H1N1) 2009 
Infection, Thailand
To the Editor: Infection with 
inﬂ   uenza A pandemic (H1N1) 2009 
has been reported worldwide follow-
ing initial identiﬁ  cation of the virus in 
April 2009 (1). The groups at highest 
risk for infection or inﬂ  uenza-related 
complications include pregnant wom-
en and children (2). We report a case 
of pandemic (H1N1) 2009 infection in 
a newborn whose mother became ill 
with pandemic (H1N1) 2009 during 
the perinatal period. 
A newborn girl showed signs of 
respiratory distress. The relevant peri-
natal history was maternal illness with 
pandemic (H1N1) 2009 7 days before 
delivery. The infant, who had a birth 
weight of 1,560 grams, was delivered 
by emergency cesarean section after 
the mother experienced cardiopulmo-
nary failure at the gestational age of 
31 weeks. Apgar scores were 9 and 
9 at 1 and 5 minutes, respectively. 
Physical examination at birth showed 
a premature infant girl with mild sub-
costal retraction. Oxygen saturation at 
room air was 91%–99%. Other results 
of the physical examination were un-
remarkable.
Initial management included rou-
tine care for premature infants. On 
the basis of the perinatal history, a 
throat swab specimen was collected 
for pandemic (H1N1) 2009 testing by 
PCR and oseltamivir, 6 mg, was ad-
ministered every 12 hours (4 mg/kg/
day). The specimen obtained from the 
throat swab was positive for pandemic 
(H1N1) 2009 by real-time PCR. The 
infant required oxygen supplemen-
tation. At day 2 of life, acute renal 
failure with an elevated plasma crea-
tinine level of 1.1 mg/dL developed in 
the infant. Chest radiograph showed 
minimal pulmonary inﬁ  ltrations. She 
was started on cefotaxime for sus-
pected sepsis. Oseltamivir dosage was 
adjusted based on the glomerular ﬁ  l-
tration rate estimated by the formula 
of Schwartz et al. (3) of 10.5 mL/
min/1.73m2 to 3 mg every 12 hours to 
complete 10 doses (2 mg/kg/day).
Infection of the patient was con-
ﬁ  rmed by real-time reverse transcrip-
tion–PCR of the throat swab specimen 
and by a 4× increase in antibodies 
against the virus by hemagglutination 
inhibition test (HI). Antibody titers 
against pandemic inﬂ  uenza  (H1N1) 
2009 by HI with turkey erythrocytes 
(4) on days 10, 24, and 42 of life were 
10, 160, and 320, respectively (Fig-
ure). At day 4 of life, repeated PCR 
performed on a throat swab specimen 
was negative for pandemic (H1N1) 
2009. Oxygen supplementation was 
gradually decreased and ﬁ  nally discon-
tinued. Her room air oxygen saturation 
was 95%–98%. Her clinical symptoms 
gradually improved. Hemoculture was 
negative after 72 hours. The antimicro-
bial drugs were given over an 8-day 
course. Plasma creatinine decreased 
to 0.9 mg/dL and 0.6 mg/dL at days 6 
and 7 of life, respectively. Her average 
urine output was 2–3 mL/kg/h. She 
was discharged at the age of 28 days 
with a body weight of 2,070 grams.
Pregnant women are one of the 
highest risk groups for inﬂ  uenza A in-
fection and inﬂ  uenza-associated com-
plications, including increased ma-
ternal and perinatal illness and death 
rates (5). Thus, pregnant women are 
given ﬁ  rst priority to receive inﬂ  uenza 
vaccination. When inﬂ  uenza develops 
in mothers during the perinatal pe-
riod, newborns can be infected trans-
placentally during maternal viremia 
or by respiratory droplets after birth. 
Transplacental infection of inﬂ  uenza 
A is rare (5), however, and there have 
been only a few case reports (6,7). 
Viremia is more frequent and more 
extensive in pregnant women due to 
depressed cell-mediated immune re-
sponse during the pregnancy (8). Our 
patient was likely infected in utero be-
cause she was delivered by cesarean 
section and was never exposed to her 
mother, who required intensive car-
diopulmonary support at the time of 
delivery. (The mother died from respi-
ratory failure 7 days after the cesarean 
section.) 
Clinical manifestations in this 
patient, including respiratory distress 
and acute renal failure, were nonspe-
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Figure. Antibody titer against inﬂ   uenza A pandemic (H1N1) 2009 by hemagglutination 
inhibition (HI) test on days 10, 24, and 42 of life of the patient. A color version of this ﬁ  gure 
is available online (www.cdc.gov/EID/content/16/2/343-F.htm).LETTERS
ciﬁ  c. The high plasma creatinine lev-
el in the newborn sometimes reﬂ  ects 
the mother’s plasma creatinine level 
(9). However, kidney function of the 
mother of the newborn was within 
normal limits at the time of Caesare-
an section; plasma creatinine level of 
0.7 mg/dL. An elevated plasma crea-
tinine level is observed frequently in 
premature infants due to immaturity 
of the kidney tissue and will usually 
decrease within a few weeks. Osel-
tamivir was administered with dose 
adjustment based on the infant’s esti-
mated glomerular ﬁ  ltration rate. The 
recommended dose of oseltamivir for 
glomerular  ﬁ   ltration rate <30 mL/
min/1.73 m2 is 2–3 mg/kg/day, based 
on preliminary data obtained by a 
National Institutes of Health–funded 
Collaborative Antiviral Study Group 
(10). The success of our manage-
ment strategy for this case suggests 
early treatment with oseltamivir can 
prevent severe illness in newborns 
with perinatal inﬂ  uenza A pandemic 
(H1N1) 2009 infection.
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Bronchial Casts 
and Pandemic 
(H1N1) 2009 Virus 
Infection
To the Editor: In the late 1990s, 
triple-reassortant inﬂ  uenza A viruses 
containing genes from avian, human, 
and swine inﬂ  uenza viruses emerged 
and became enzootic in swine herds 
in North America (1). The ﬁ  rst 11 hu-
man cases of novel inﬂ  uenza A virus 
infection were reported to the Centers 
for Disease Control and Prevention 
(CDC; Atlanta, GA, USA) from De-
cember 2005 through February 2009 
(1). In response to those reports, sur-
veillance for human infection with 
nonsubtypeable inﬂ  uenza  A  viruses 
was implemented.
In the spring of 2009, outbreaks 
of febrile respiratory infections caused 
by a novel inﬂ  uenza A virus (H1N1) 
were reported among persons in Mex-
ico, the United States, and Canada (2). 
Patient specimens were sent to CDC 
for real-time reverse transcription–
PCR (RT-PCR) testing, and from April 
15 through May 5, 2009, a total of 642 
infections with the virus, now called 
pandemic (H1N1) 2009 virus, were 
conﬁ  rmed. Of those 642 patients, 60% 
were <18 years of age, indicating that 
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